Plasma Protein Therapeutics Market Size, Share, Trends, Growth 2032

Table Of Content

Methodology

Free Analysis

Plasma is the single largest component made up of 90% of water and has enzymes, salts, antibodies, and other proteins. It can be defined as the clear, straw-colored fluid part of the blood which residue after red platelets, blood cells, white blood cells, and other cellular components are eliminated. Plasma proteins have different functions, including transport of different biochemicals (lipids, hormones, etc.) in the circulatory system; some functions of the plasma protein include blood clotting, fighting against diseases, and other vital functions. Various proteins are present in the plasma of human blood. A blend of simple proteins, lipoproteins, glycoproteins, and other additional conjugated proteins are called as plasma proteins. Plasma protein therapy is an inimitable biological medicine; it has a biochemical profile because of which it differs in processing and production methods and thus is used for the treatment of various genetic, life-threatening chronic and rare diseases.

According to the Plasma Protein Therapeutics Association (PPTA), plasma proteins are used in a variety of rare diseases treatment such as primary immunodeficiency disease, alpha-1 antitrypsin deficiency, and hemophilia A. It can also be used to treat conditions such as shocks & burns, Rh incompatibility, organ transplants, pediatric HIV, trauma, cardiopulmonary issues, liver conditions, and animal bites; they are also used in major surgeries. Hemophilia disease occurs in about 1 of every 5,000 male births, at present about 20,000 males in the U.S are living with the disorder. These plasma proteins play a vital function in clotting and providing immunity against the diseases. 

The major driver for the plasma protein therapeutic market is the growing application of the plasma proteins derivative medicines. Development of novel plasma-derived therapies is another major driver for the growth of this market. Rising prevalence of life-threatening diseases including immune or neurological system such as chronic inflammatory demyelinating polyneuropathy (CIPD), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), and other infectious diseases are expected to drive the plasma protein therapeutic market growth. Additionally, modernization in the technologies provided efficient and cost-effective methods for fractionating the proteins from plasma, which is expected to boost the market growth. Implementation of stringent regulatory policies and issues pertaining to reimbursements are likely to inhibit the market’s trajectory. The existing complexity in biologics manufacturing is also expected to create threats for the market.

Based on product type, the plasma protein therapeutic market has been segmented into coagulation factors, immunoglobulin, alpha-1 proteinase inhibitor, and albumin. Based on application, the plasma protein therapeutic market can be divided into hemophilia, primary immunodeficiency disorder, idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema, and other indications (Kawasaki disease, GBS, CIDP). Growing government initiatives, increased awareness among the healthcare practitioners, and growing disposable income of the patients are some of the factors that drive the global market for plasma protein therapeutic.

According to the Plasma Protein Therapy Association (PPTA), North America region gained up to 40% of the market in 2013 and is expected to dominate the plasma protein therapeutic market with the highest amount of blood collection. Europe is the second largest market in the global plasma protein therapeutics market. Due to the increasing awareness about blood donations, Asia Pacific is expected to witness a noteworthy growth for the forecast period. Some of the most lucrative markets for plasma protein therapeutics in Europe include Switzerland, Germany, Spain, Italy, France, Sweden, and the U.K.

Some of the key players in plasma protein therapeutic market include Octapharma, CSL Limited, Baxter, Telecris, Grifols, LFB Group, Kedrion, and Chengdu Inst; Japan Red Cross, Shanghai Blood Institute, BPL Group, and Sanquin are some of the nonprofit organizations which are playing an important role in plasma protein therapeutic market.